Clinical Trials Logo
  1. Home
  2. KRAS Gene Mutation
  3. NCT02818725

I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations — GETUG-AFU19  

KRAS Gene Mutation Clinical Trial

Official title:
Intensified Methotrexate, Vinblastine, Doxorubicin and Cisplatin +/-Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma in Patients Without Harvey Nor Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations. Phase II Study

Clinical Trial Summary

OBJECTIVES OF THE TRIAL Primary objective Evaluation of efficacy in terms of progression-free survival at 9 months of the combination of intensified methotrexate, vinblastine, doxorubicin and cisplatin with or without panitumumab as first-line treatment of advanced urothelial carcinoma in patients without Harvey nor Kirsten rat sarcoma viral oncogene homolog mutations. Secondary objectives - To assess toxicity - To assess response rate - To assess overall survival - To assess time to progression - To study the correlation between response rate, time to progression, overall survival and biological parameters

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02818725
Study type Interventional
Source UNICANCER
Contact
Status Completed
Phase Phase 3
Start date June 2010
Completion date September 2017
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04965818 - Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer Phase 1
Recruiting NCT03808558 - Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas Phase 2
Completed NCT03704688 - Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03065387 - Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Phase 1
Completed NCT03829410 - Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation Phase 1/Phase 2
Active, not recruiting NCT03299088 - Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations Phase 1
Completed NCT03965845 - A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03750175 - OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -
Active, not recruiting NCT02642042 - Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer Phase 2
Not yet recruiting NCT03777124 - Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer Phase 2
Active, not recruiting NCT03087071 - Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer Phase 2
Completed NCT03520842 - Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer Phase 2
Completed NCT03171636 - Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients
Completed NCT01700582 - French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings
Completed NCT02964689 - Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC. Phase 1
No longer available NCT04446793 - Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer